Key facts
- Virometix’s last known valuation is $22.8M (Jul 2020).
- It has raised $33.8M; the latest was Later Stage VC ($15.0M) in Nov 2025.
- Notable investors include Venture Kick, University of Zürich.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Virometix
- ·The full record, as it builds
Funding rounds
No funding rounds for Virometix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Virometix
Developer of vaccines and immunotherapeutic drugs designed to prevent and treat infections and chronic human diseases. The company's vaccines and immunotherapeutic drugs integrate rational molecular design, chemical synthesis, and proprietary synthetic particle technology for rapid production and optimization, enabling doctors and physicians to combat newly arising complex viral and bacterial pathogens.
- Sector
- Healthcare
- HQ
- Schlieren, Switzerland
- Founded
- 2009
- Employees
- 15
- Website
- virometix.com/
- Ownership
- Privately Held (backing)
Virometix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Virometix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Virometix in its N-PORT filings yet. We sweep new filings monthly.